Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Sana Biotechnology, Inc. (NASDAQ:SANA – Free Report) by 17.9% during the 3rd quarter, Holdings Channel.com reports. The firm owned 35,196 shares of the company’s stock after acquiring an additional 5,338 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Sana Biotechnology were worth $146,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its position in shares of Sana Biotechnology by 26.5% in the second quarter. Bank of New York Mellon Corp now owns 431,744 shares of the company’s stock valued at $2,357,000 after purchasing an additional 90,423 shares during the period. Rhumbline Advisers raised its holdings in Sana Biotechnology by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 181,903 shares of the company’s stock valued at $993,000 after acquiring an additional 25,056 shares during the period. Arizona State Retirement System lifted its position in shares of Sana Biotechnology by 36.7% during the second quarter. Arizona State Retirement System now owns 37,028 shares of the company’s stock worth $202,000 after acquiring an additional 9,940 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Sana Biotechnology in the second quarter worth $100,000. Finally, Ensign Peak Advisors Inc purchased a new position in shares of Sana Biotechnology in the second quarter valued at $372,000. Institutional investors own 88.23% of the company’s stock.
Wall Street Analysts Forecast Growth
SANA has been the topic of a number of recent research reports. JMP Securities cut Sana Biotechnology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of Sana Biotechnology in a report on Wednesday, November 27th.
Sana Biotechnology Stock Performance
Shares of SANA stock opened at $2.65 on Tuesday. The company has a market capitalization of $591.67 million, a PE ratio of -1.89 and a beta of 1.33. Sana Biotechnology, Inc. has a 52-week low of $2.28 and a 52-week high of $12.00. The business’s fifty day moving average is $3.32 and its 200 day moving average is $4.84.
Sana Biotechnology (NASDAQ:SANA – Get Free Report) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.01. On average, sell-side analysts forecast that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.
Insider Buying and Selling at Sana Biotechnology
In other Sana Biotechnology news, Director Richard Mulligan sold 150,000 shares of the firm’s stock in a transaction dated Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total transaction of $612,000.00. Following the sale, the director now owns 2,848,121 shares in the company, valued at $11,620,333.68. This trade represents a 5.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 31.10% of the stock is currently owned by company insiders.
About Sana Biotechnology
Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.
Featured Articles
- Five stocks we like better than Sana Biotechnology
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- How to Master Trading Discipline: Overcome Emotional Challenges
- Insider Trades May Not Tell You What You Think
- Does China Investigation Change NVIDIA’s Outlook; Yes, No, Maybe?
- What Are Dividend Contenders? Investing in Dividend Contenders
- Is Marvell Technology Chipping Away at NVIDIA’s Market Lead?
Want to see what other hedge funds are holding SANA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sana Biotechnology, Inc. (NASDAQ:SANA – Free Report).
Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.